<p><strong>ProQR Therapeutics N.V.</strong>（纳斯达克代码：PRQR）的股东们看到股价在过去一个月内大幅下跌 29%，并且抹去了之前的正面表现，肯定不会感到高兴。在过去 30 天内的下跌为股东们带来了艰难的一年，期间股价下跌了 42%。</p>
<p>尽管其股价大幅下跌，但可以说 ProQR Therapeutics 目前的市销率（&#34;P/S&#34;）为 11.7 倍，与美国生物科技行业的中位数 P/S 比率约为 11.6 倍相比，似乎仍然处于&#34;中等水平&#34;。然而，如果没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 ProQR Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/224193775-ps-multiple-vs-industry-1-dark-2/1763980106839?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/224193775-ps-multiple-vs-industry-1-dark-2/1763980106839"/></p>
<p>纳斯达克 CM:PRQR 市销率与行业比较 2025 年 11 月 24 日</p>
<h3>ProQR Therapeutics 最近的表现如何？</h3>
<p>尽管行业最近经历了收入增长，ProQR Therapeutics 的收入却出现了下滑，这并不好。也许市场在期待其糟糕的收入表现会改善，从而使 P/S 未能下跌。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到损失。</p>
<p>想要了解分析师对公司的估计的完整情况吗？那么我们 <strong>免费的</strong>ProQR Therapeutics 报告将帮助您揭示未来的趋势。</p>
<h2>收入增长指标告诉我们关于 P/S 的什么？</h2>
<p>您唯一会对 ProQR Therapeutics 的 P/S 感到满意的时刻，是当公司的增长与行业紧密相连时。</p>
<p>回顾过去一年，公司收入下降了令人沮丧的 13%。令人瞩目的是，尽管在过去 12 个月中经历了挫折，三年的收入增长却大幅提升。因此，股东们会感到高兴，但也会对过去 12 个月有一些严肃的问题需要思考。</p>
<p>展望未来，六位分析师预计未来三年每年将实现 54% 的增长。这一增长预期显著低于更广泛行业的 124% 的年增长预测。</p>
<p>鉴于此，ProQR Therapeutics 的 P/S 与大多数其他公司持平，这令人好奇。显然，许多投资者对公司的看法并不像分析师所暗示的那样悲观，并且目前不愿意抛售他们的股票。如果 P/S 降至与增长前景更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
<h2>ProQR Therapeutics 的 P/S 底线</h2>
<p>随着股价暴跌，ProQR Therapeutics 的 P/S 似乎与其他生物科技行业的公司相当。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>我们对 ProQR Therapeutics 收入前景的分析显示，其较差的收入前景并没有像我们预期的那样对其 P/S 产生负面影响。目前，我们对 P/S 并不乐观，因为预测的未来收入不太可能长期支持更积极的情绪。这使得股东的投资面临风险，潜在投资者也可能面临支付不必要溢价的危险。</p>
<p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>ProQR Therapeutics 的 1 个警示信号</strong>，理解这一点应成为您投资过程的一部分。</p>
<p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费的</strong> 其他强劲盈利增长和低市盈率公司的集合。</p>

ProQR治疗

<p>ProQR Therapeutics N.V.（纳斯达克代码：PRQR）股价下跌 29%，引发了对投资风险的担忧。尽管其市销率为 11.7 倍，与生物技术行业的中位数相符，但公司的收入却出现下降，与行业增长形成对比。分析师预测 ProQR 的增长将低于行业水平，暗示可能存在高估的风险。如果市销率调整以反映增长前景，投资者可能面临未来失望。股价的暴跌突显了投资风险，ProQR 被识别出一个警示信号</p>

<p><strong>ProQR Therapeutics N.V.</strong> (NASDAQ:PRQR) shareholders won't be pleased to see that the share price has had a very rough month, dropping 29% and undoing the prior period's positive performance. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 42% in that time.</p>
<div class="lb-trans"><p><strong>ProQR Therapeutics N.V.</strong>（纳斯达克代码：PRQR）的股东们看到股价在过去一个月内大幅下跌 29%，并且抹去了之前的正面表现，肯定不会感到高兴。在过去 30 天内的下跌为股东们带来了艰难的一年，期间股价下跌了 42%。</p>
</div><p>Although its price has dipped substantially, it's still not a stretch to say that ProQR Therapeutics' price-to-sales (or &#34;P/S&#34;) ratio of 11.7x right now seems quite &#34;middle-of-the-road&#34; compared to the Biotechs industry in the United States, where the median P/S ratio is around 11.6x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.</p>
<div class="lb-trans"><p>尽管其股价大幅下跌，但可以说 ProQR Therapeutics 目前的市销率（&#34;P/S&#34;）为 11.7 倍，与美国生物科技行业的中位数 P/S 比率约为 11.6 倍相比，似乎仍然处于&#34;中等水平&#34;。然而，如果没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>Check out our latest analysis for ProQR Therapeutics</p>
<div class="lb-trans"><p>查看我们对 ProQR Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/224193775-ps-multiple-vs-industry-1-dark-2/1763980106839" alt="" original-src="https://images.simplywall.st/asset/chart/224193775-ps-multiple-vs-industry-1-dark-2/1763980106839"/></p>
<p>NasdaqCM:PRQR Price to Sales Ratio vs Industry November 24th 2025</p>
<div class="lb-trans"><p>纳斯达克 CM:PRQR 市销率与行业比较 2025 年 11 月 24 日</p>
</div><h3>What Does ProQR Therapeutics' Recent Performance Look Like?</h3>
<div class="lb-trans"><h3>ProQR Therapeutics 最近的表现如何？</h3>
</div><p>While the industry has experienced revenue growth lately, ProQR Therapeutics' revenue has gone into reverse gear, which is not great. Perhaps the market is expecting its poor revenue performance to improve, keeping the P/S from dropping. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>尽管行业最近经历了收入增长，ProQR Therapeutics 的收入却出现了下滑，这并不好。也许市场在期待其糟糕的收入表现会改善，从而使 P/S 未能下跌。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到损失。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on ProQR Therapeutics will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的估计的完整情况吗？那么我们 <strong>免费的</strong>ProQR Therapeutics 报告将帮助您揭示未来的趋势。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于 P/S 的什么？</h2>
</div><p>The only time you'd be comfortable seeing a P/S like ProQR Therapeutics' is when the company's growth is tracking the industry closely.</p>
<div class="lb-trans"><p>您唯一会对 ProQR Therapeutics 的 P/S 感到满意的时刻，是当公司的增长与行业紧密相连时。</p>
</div><p>Retrospectively, the last year delivered a frustrating 13% decrease to the company's top line. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, despite the drawbacks experienced in the last 12 months. Accordingly, shareholders will be pleased, but also have some serious questions to ponder about the last 12 months.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入下降了令人沮丧的 13%。令人瞩目的是，尽管在过去 12 个月中经历了挫折，三年的收入增长却大幅提升。因此，股东们会感到高兴，但也会对过去 12 个月有一些严肃的问题需要思考。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 54% each year as estimated by the six analysts watching the company. That's shaping up to be materially lower than the 124% each year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未来，六位分析师预计未来三年每年将实现 54% 的增长。这一增长预期显著低于更广泛行业的 124% 的年增长预测。</p>
</div><p>In light of this, it's curious that ProQR Therapeutics' P/S sits in line with the majority of other companies. Apparently many investors in the company are less bearish than analysts indicate and aren't willing to let go of their stock right now. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>鉴于此，ProQR Therapeutics 的 P/S 与大多数其他公司持平，这令人好奇。显然，许多投资者对公司的看法并不像分析师所暗示的那样悲观，并且目前不愿意抛售他们的股票。如果 P/S 降至与增长前景更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
</div><h2>The Bottom Line On ProQR Therapeutics' P/S</h2>
<div class="lb-trans"><h2>ProQR Therapeutics 的 P/S 底线</h2>
</div><p>With its share price dropping off a cliff, the P/S for ProQR Therapeutics looks to be in line with the rest of the Biotechs industry. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>随着股价暴跌，ProQR Therapeutics 的 P/S 似乎与其他生物科技行业的公司相当。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>Our look at the analysts forecasts of ProQR Therapeutics' revenue prospects has shown that its inferior revenue outlook isn't negatively impacting its P/S as much as we would have predicted. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. This places shareholders' investments at risk and potential investors in danger of paying an unnecessary premium.</p>
<div class="lb-trans"><p>我们对 ProQR Therapeutics 收入前景的分析显示，其较差的收入前景并没有像我们预期的那样对其 P/S 产生负面影响。目前，我们对 P/S 并不乐观，因为预测的未来收入不太可能长期支持更积极的情绪。这使得股东的投资面临风险，潜在投资者也可能面临支付不必要溢价的危险。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>1 warning sign with ProQR Therapeutics</strong>, and understanding should be part of your investment process.</p>
<div class="lb-trans"><p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>ProQR Therapeutics 的 1 个警示信号</strong>，理解这一点应成为您投资过程的一部分。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费的</strong> 其他强劲盈利增长和低市盈率公司的集合。</p>
</div>

ProQR Therapeutics N.V.（纳斯达克代码：PRQR）股价暴跌 29% 可能意味着存在一定风险